New search Hide text from Guidelines
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSThis group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
L01 ANTINEOPLASTIC AGENTS
Combination products are classified in L01XY - Combinations of antineoplastic agents, except for combinations of monoclonal antibodies or antibody drug conjugates which are classified in L01FY.
Detoxifying agents used in connection with high dose treatment of antineoplastic agents are classified in V03AF (e.g. calcium folinate).
Radiopharmaceuticals used in the treatment of cancer are classified in V10X.
| DDDs have been established for the protein kinase inhibitors in L01E only. No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X. This is because of highly individualised use and wide dosage ranges. The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy. The consumption of antineoplastic agents is in some countries measured in grams. This is recommended as a method to be used internationally for these particular agents. |
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Monoclonal antibodies mainly indicated for the treatment of cancer are classified in this group.
Monoclonal antibodies combined with hyaluronidase are classified at the same 5th level as the plain monoclonal antibody.
L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Bevacizumab used in age-related macular degeneration (AMD) is classified in S01LA08.
| ATC code | Name | DDD | U | Adm.R | Note |
| L01FG01 | bevacizumab |
Last updated: 2024-01-26